M.S., Columbia University
B.Pharm., Dhaka University, Bangladesh
Abu Serajuddin, Ph.D, joined St. John’s University in September 2008 as Professor of Industrial Pharmacy after working for over 3 decades in the pharmaceutical industry in scientific and managerial positions. After joining the pharmaceutical industry as an Associate Senior Scientist in Revlon Health Care (later part of Sanofi-Aventis through mergers) in 1976, Dr. Serajuddin rose to the position of Director/Executive Director and the US Head of Drug Product Development for Novartis Pharmaceuticals Corp. in 1999, and later, from 2003 to 2008, he served as the Executive Director of Science, Technology & Outsourcing (STO) for the company with global responsibilities of developing drug delivery and pharmaceutical processing technologies, managing science and technology (Head, Science & Technology Forum), and outsourcing of pharmaceutical product development and pharmaceutical analysis (US only). He formulated and developed numerous pharmaceutical products, many with extremely difficult and challenging development issues. Several products that he developed or co-developed attained blockbuster status in the market.
Prior to joining Novartis in 1999, Serajuddin worked for 12 years in Bristol-Myers Squibb (BMS) and 10 years in Sanofi-Aventis (through mergers). For his leadership in the acceleration of drug product development at BMS, he received Productivity for Growth Award, which was one of the top corporate-level recognitions given by BMS to its employees. In addition, he received the BMS President's Award for unprecedented 3 times for his contribution and leadership in solving difficult drug product development issues.
During the past 8 years at St. John’s University, Dr. Serajuddin has built an outstanding teaching and research program dedicated to the development of drug delivery systems and pharmaceutical processing technologies. His special expertise is in the development of poorly water-soluble drugs by using lipid based systems, solid dispersion, melt extrusion, nanotechnology, salt and co-crystal formation, etc. His research program also includes the melt granulation technology and the continuous manufacturing of solid dosage forms. He helped the University in establishing the Industrial Pharmaceutical Innovation Laboratory dedicated to these research activities by raising funds from alumni and the pharmaceutical industry.
Dr. Abu Serajuddin authored over 100 research papers, book chapters and patents, having 6000 citations, and made about 125 invited presentations in major scientific conferences in the USA and other parts of the world. He is a co-inventor in 13 patents. One of his publications [J. Pharm. Sci. 88:1058-1066 (1999)] was identified by the Journal of Pharmaceutical Sciences as one of the 10 outstanding papers published by the Journal in the decade of 1990s; the paper has received over 1458 citations.
Dr. Serajuddin is internationally recognized for his contribution to pharmaceutical sciences, especially to (a) the development of poorly water-soluble drugs, (b) formulation design and development, and (c) pharmaceutical processing. For his research achievements, he received three of the most distinguished awards given by the American Association of Pharmaceutical Scientists (AAPS): AAPS Research Achievement Award for Formulation Design and Development (FDD) in 2010, AAPS Research Achievement Award for Manufacturing Science and Engineering (MSE) in 2014, and AAPS Lipid-Based Drug Delivery Outstanding Research Award in 2015. Recently, in 2016, he was the recipient of the IPEC Ralph Shangraw Memorial Award, the highest scientific recognition given by the International Pharmaceutical Excipients Council (IPEC) for research on pharmaceutical excipients and excipient-related technologies (IPEC is a global trade organization comprised of over 200 pharmaceutical companies and excipient manufacturers). He also received the Distinguished Pharmaceutical Scientist Award (2004) from the American Association of Indian Pharmaceutical Scientists (AAiPS). Further, Novartis Pharmaceuticals Corp. named him Novartis Leading Scientist, a top honor bestowed by the company for extraordinary contribution to the development and growth of the company through scientific excellence. Additionally, in recognition of his scientific and professional contributions, Dr. Serajuddin attained Fellow status in American Association of Pharmaceutical Scientists (AAPS), American Pharmacists Association (APhA), International Union of Pure and Applied Chemistry (IUPAC), and American Association of Indian Pharmaceutical Scientists (AAiPS). He serves in Editorial Advisory Boards of Journal of Pharmaceutical Sciences and Journal of Pharmaceutical Excipients and Food Chemicals. Serajuddin is a Charter Member of the American Association of Pharmaceutical Scientists (AAPS).
Among many professional leadership positions, Dr. Serajuddin chaired the AAPS Pharmaceutics and Drug Delivery (PDD) Section in 2001 and AAPS Preformulation Focus Group in 1994-96. He served, from 2006 to 2009, as the Chair of Fellows Selection Committee of FDD/PDD Sections and, from 2011 to 2015, as the chair of the FDD Awards committee of AAPS.